5Ј GTAAAGGATCAAGTGCTGTGC 3Ј) or U3-R-poly(A) not detect transcribed IDDMK 1,2 22 endogenous retrovi-(5Ј TTTTTGAGTCCCCTTAGTATTTATT 3Ј). They stated rus in EDTA plasma. All PCR product from plasma RNA that the U3 and R primers detected genomic IDDMK 1,2 22, appears to derive from contaminating DNA and is not whereas U3 and R-poly(A) primers detected only viral type 1 diabetes (preclinical or clinical)-specific. Our retranscripts. In an attempt to reproduce these latter data, sults do not, however, necessarily refute the proposition we report here the results of experiments carried out that endogenous retroelements, identical or similar to independently in laboratories in Melbourne, Pittsburgh, IDDMK 1,2 22, might encode a SAG responsible for skewand London. It must be emphasized that the three laboing of the T cell receptor V␤ repertoire in the islet infiltrate ratories only attempted to reproduce and extend the of the type 1 diabetes patients as reported by Conrad results of Conrad et al. (1997) on peripheral blood and et al. (1997) . not those on the isolation of retroviral particles from
In Pittsburgh, in order to extend the results of Conislets and islet-infiltrating lymphocytes from patients rad et al. (1997), we designed primers that amplify the with type 1 diabetes.
sequence encoding the reported superantigen of In Melbourne, we used the exact protocol of Conrad IDDMK 1,2 22. The sequences of the primers, CCTCCACG et al. (1997) , or modified protocols, to confirm that GAGATGGTAA and TCGAGGTGCCTAATCTATAATAGT, IDDMK 1,2 22 transcripts are present in the plasma of indimatched the sequence in the region of the ATG and viduals with preclinical or clinical type 1 diabetes. We TAG, start and stop codons, and were first tested on purified total RNA from EDTA plasma of two individuals genomic DNA. Cloning and sequencing of the amplified with preclinical type 1 diabetes (a male aged 7 and a products yielded eight unique sequences from nine female aged 18, each of whom had a sibling with type 1 clones, one of which was identical to the reported SAG. diabetes and circulating antibodies to the islet antigens, We then tested, by RT-PCR, RNA extracted from sera insulin and glutamic acid decarboxylase [GAD]), three and EDTA plasma and peripheral blood lymphocytes (PBL) of five Caucasoid high-risk individuals (siblings of recently-diagnosed patients (females age 5, 9, and 10, diabetic probands, carrying type 1 diabetes susceptibilSubsequently, the U3-R-poly(A) primer amplified the expected product of 489 bp by RT-PCR on RNA exity HLA class II alleles, positive for autoantibodies to the islet antigens GAD65 and tyrosine phosphatase IA-2, tracted from PBL of four out of five newly diagnosed patients. However, ribonuclease A treatment did not and with impaired glucose tolerance), ten recent-onset type 1 diabetes patients (within one week of clinical prevent amplification, suggesting the presence of DNA contamination in the samples. Ribonuclease treatment diagnosis) and 12 age-matched nondiabetic controls. Thus, our tested samples came from patients at the eliminated the RT-PCR product from positive control RNA (supplied in Access RT-PCR Kit, cat. no 1260, Prosame stage of their disease as those tested by Conrad et al. (1997) . Poly(A)-RNA was separated from total RNA mega, USA). The U3-R-poly(A) primer also amplified a product of that had first been treated with DNase. It was then reverse transcribed using the R-poly(A) primer described 489 bp, using the same PCR conditions, but without the RT step, on DNA extracted from the same PBL of newly by Conrad et al. (1997) . After PCR amplification using the above primers, bands of 489 bp were frequently, diagnosed patients. When an RNA sample positive in RT-PCR with the U3-R-poly(A) primers was pretreated though not always, found in patient samples (100% of high-risk individuals and 50% of recent-onset patients).
with RNase-free DNase, the 489 bp product was eliminated. With the same conditions, it was still possible Most importantly, however, they were also found in seven out of twelve (58%) of control samples. Cloning to obtain amplification from the positive control RNA, showing that the elimination of the signal was not due and sequencing of the PCR products revealed two dominant sequences, present in some samples from both to RNase contaminating the DNase. Hence, in our hands, the U3-R-poly(A) primer amplified DNA and we suggest patients and controls, which were very similar to HERV-K10 and to IDDMK 1,2 22. These sequences mismatched that the amplification we observed in our RT-PCR samples was due to trace contamination of DNA. HERV-K10 by 8 and 4 nucleotides and IDDMK 1,2 22 by 8 and 13 nucleotides. None of the clones contained a
The same RT-PCR conditions were used with the U3 primer and a novel viral RNA-specific oligo-dT primer sequence that exactly matched the IDDMK 1,2 22 sequence. When the PCR was performed with either of of the sequence 5Ј-3Ј TTTTTTTTTTTTTTTTTTTTGA GTC. A product of approximately 489 bp size was obtwo alternative primers, which are downstream of the stop codon, TCCCAAGGGTAGAAAGACTG and the U3-tained with RNA from two out of three PBL samples from newly diagnosed patients and was eliminated by R-poly(A) primer, the same two sequences were again most frequent. In addition, they were found to not enribonuclease treatment. In order to confirm specificity for RNA, PCR was performed without the RT step and code the stop codon characteristic of IDDMK 1,2 22, but rather the same codon, TGG, which is present in HERVwas negative on DNA from the same PBL. The same RT-PCR conditions were also applied using the U3 primer K10. Again, none of the other less frequently obtained clones matched exactly the IDDMK 1,2 22 sequence.
together with a long oligo dT primer [5Ј pd(T) 25-30 3Ј] . A product of approximately 489 bp was again obtained Thus, based on the amplification of purified genomic DNA, we confirmed the presence of an endogenous with the same PBL RNA from two out of three newly diagnosed patients. PCR performed on DNA in the same sequence matching that which would encode the reported superantigen. However, if the corresponding conditions, but without the RT step, detected a product of the same size in one out of five samples of newly RNA is expressed, it is frequently not the most abundantly expressed HERV-K10-like species and, therefore, diagnosed patients. This sample was also positive in RT-PCR and possibly contains an integrated (endogenous) may not easily be detected in the presence of the other more abundant sequences. Furthermore, these very retrovirus with poly(A) tail. When RNA from PBL of normal individuals were analyzed, with either the U3-oligo similar sequences are not specifically expressed in type 1 diabetes, as they are frequently detected in control dT virus-specific primer or the oligo dT 25-30 primer, products of approximately 489 bp were obtained in two samples. We do not interpret these findings to necessarily negate a potential etiological role of retroviruses or of three and three of three cases, respectively; i.e., the product, in this case, was not disease specific. superantigens in type 1 diabetes, rather to question the epidemiologic value of nonspecific retroviral sequence In summary, our experiments indicate that the U3-Rpoly(A) primers described by Conrad et al. (1997) are detection in patients' plasma.
In London, we initially performed survey studies, by not RNA specific, but also amplify DNA, and we could detect viral RNA sequences in both newly diagnosed means of genomic PCR and RT-PCR based on the published primer sequences from the IDDMK 1,2 22 novel rettype 1 diabetes patients and normal controls using our modified RNA-specific primers. roviral genome. Genomic DNA was subjected to PCR with the U3 and R primers. Primers U3 R1 and U3 R2 RNA transcripts for multiple endogenous retroviral elements are expressed in normal and disease tissues amplified products of the size described by Conrad et al. (1997) (300 and 395 bp) on DNA samples extracted (Nakagawa et al., 1997) . The genomic complexity and multiple potential pathogenic mechanisms of endogefrom PBL of 10 age-matched normal individuals and five newly diagnosed (within one week of clinical onset) type nous retroviruses (Nakagawa and Harrison, 1996) suggest that experimental strategies will need to be re-1 diabetes patients. The patients, two Caucasoids and three Africans, were sero-positive for islet cell antibodfined, in order to unravel their possible involvement in the pathogenesis of type 1 diabetes (Bottazzo, 1993) . ies (ICA), by indirect immunofluorescence on sections of human blood group 0 pancreas, and for antibodies
We are unable to confirm that the strategy of Conrad et al. (1997) identifies type 1 diabetes-specific, novel to GAD and tyrosine phosphatase IA-2, and all carried type 1 diabetes susceptibility HLA class II alleles. IDDMK 1,2 22 retroviral RNA in plasma.
